Emcure Pharmaceuticals Expands Poviztra Use for MASH Indication
Emcure Pharmaceuticals Ltd announced that its co-marketed brand Poviztra®, containing innovator semaglutide, has received CDSCO approval for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3). This approval makes semaglutide the first GLP-1 receptor agonist approved in India for MASH, addressing a significant unmet medical need. Poviztra® is manufactured and imported from Novo Nordisk's European facility. The expansion leverages Emcure's subsidiary Zuventus Healthcare's portfolio to increase MASH awareness, diagnosis, and treatment. The approval is supported by Phase III ESSENCE trial data showing semaglutide's efficacy in resolving steatohepatitis and improving liver fibrosis. This marks an important milestone for patients with this serious liver disease.
Key Highlights
- CDSCO approves Poviztra® (semaglutide) for MASH treatment in India.
- First GLP-1 receptor agonist approved for MASH in the Indian market.
- Addresses significant unmet medical need for progressive liver disease.
- Leverages innovator molecule from Novo Nordisk, manufactured in Europe.
- Expands Emcure's portfolio in complex metabolic and liver diseases.
Price Impact
More from EMCURE